VA
TCRX icon

Verdad Advisers’s TScan Therapeutics TCRX Stock Holding History

Verdad Advisers’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$135K Buy
+134,001
New +$143K 0.15% 144

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Verdad Advisers's TCRX Position: Q1 2026 in Review

Verdad Advisers opened a new position in TScan Therapeutics (TCRX) in Q1 2026: 134,001 shares worth $135K. The stake represents 0.15% of the portfolio and ranks #144 among its holdings.

60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • Verdad Advisers held 134,001 shares of TScan Therapeutics worth $135K as of Q1 2026.
  • TScan Therapeutics was a new Verdad Advisers position in Q1 2026.
  • TScan Therapeutics made up 0.15% of Verdad Advisers's portfolio in Q1 2026, its #144 holding.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Verdad Advisers's 13F filing for Q1 2026, filed 15 May 2026.